Raloxifene
- CAS No.
- 84449-90-1
- Chemical Name:
- Raloxifene
- Synonyms
- RALOXIFEN;Evista;RALOXAFINE;RALOXIFENE;RALOXIFENE-D7;Raloxifene CRS;LY156758 free base;Raloxifene USP/EP/BP;Raloxifene hydrochlo;99% Purity Raloxifene
- CBNumber:
- CB1290431
- Molecular Formula:
- C28H27NO4S
- Molecular Weight:
- 473.58
- MDL Number:
- MFCD00866415
- MOL File:
- 84449-90-1.mol
- MSDS File:
- SDS
Melting point | 250-253°C |
---|---|
Boiling point | 728.2±60.0 °C(Predicted) |
Density | 1.289±0.06 g/cm3(Predicted) |
storage temp. | Desiccate at +4°C |
solubility | DMSO: 28 mg/mL, soluble |
form | solid |
pka | 8.83±0.15(Predicted) |
color | light yellow |
Water Solubility | 560μg/L at 25℃ |
LogP | 6.09 |
CAS DataBase Reference | 84449-90-1(CAS DataBase Reference) |
NCI Dictionary of Cancer Terms | Evista |
FDA UNII | YX9162EO3I |
NCI Drug Dictionary | Evista |
ATC code | G03XC01 |
SAFETY
Risk and Safety Statements
Symbol(GHS) | ![]() ![]() ![]() GHS08,GHS09,GHS06 |
---|---|
Signal word | Danger |
Hazard statements | H411-H360-H311 |
Precautionary statements | P280-P302+P352-P312-P322-P361-P363-P405-P501 |
WGK Germany | 3 |
HS Code | 29349990 |
Raloxifene price
Manufacturer | Product number | Product description | CAS number | Packaging | Price | Updated | Buy |
---|---|---|---|---|---|---|---|
TRC | R099995 | Raloxifene | 84449-90-1 | 100mg | $75 | 2021-12-16 | Buy |
TRC | R099995 | Raloxifene | 84449-90-1 | 1g | $105 | 2021-12-16 | Buy |
Usbiological | 464501 | Raloxifene | 84449-90-1 | 100mg | $355 | 2021-12-16 | Buy |
TRC | R099995 | Raloxifene | 84449-90-1 | 5g | $470 | 2021-12-16 | Buy |
American Custom Chemicals Corporation | API0003075 | KEOXIFENE 95.00% | 84449-90-1 | 50MG | $164.85 | 2021-12-16 | Buy |
Raloxifene Chemical Properties,Uses,Production
Application in Particular Diseases
In Osteoporosis:
- Raloxifene is an estrogen agonist on bone but an antagonist on the breast and uterus. It is approved for prevention and treatment of postmenopausal osteoporosis. Other estrogen agonists/antagonists may be approved soon (e.g., bazedoxifene, lasofoxifene).
- Raloxifene decreases vertebral fractures and increases spine and hip BMD, but to a lesser extent than bisphosphonates. After discontinuation, the beneficial effect is lost and bone loss returns to age- or disease-related rates.
- Raloxifene (like tamoxifen) is associated with decreased breast cancer risk. Raloxifene is associated with decreases in total and low-density lipoprotein cholesterol, neutral effects on high-density lipoprotein cholesterol, but slight increases in triglycerides; no beneficial cardiovascular effects have yet been demonstrated.
- Raloxifene is well tolerated overall. Hot flushes occur more frequently in women recently finishing menopause or discontinuing estrogen therapy (ET). Endometrial bleeding occurs rarely. Raloxifene is contraindicated in women with an active or past history of venous thromboembolism. Therapy should be stopped if a patient anticipates extended immobility.
Chemical Properties
Light-Yellow Solid
Uses
A nonsteroidal estrogen receptor mixed agonist/antagonist
Uses
Raloxifene is a nonsteroidal, selective estrogen receptor modulator (SERM). Antiosteoporotic.
Indications
Raloxifene (Evista) is a new SERM approved for use in the treatment and prevention of osteoporosis because it has estrogenic activity in bone. Raloxifene is an estrogen antagonist in both breast and endometrial tissues. The estrogenlike properties of raloxifene result in the maintenance of a favorable serum lipid profile (decreased low-density lipoprotein levels with no change in either high-density lipoproteins or triglycerides). Raloxifene is 95% bound to plasma proteins. Absorption of raloxifene is impaired by cholestyramine.
Definition
ChEBI: A member of the class of 1-benzothiophenes that is 1-benzothiophene in which the hydrogens at positions 2, 3, and 6 have been replaced by p-hydroxyphenyl, p-[2-(piperidin-1-yl)ethoxy]benzoyl, and hydroxy groups, respectively.
brand name
Evista (Lilly).
General Description
Raloxifene, [6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thien-3-yl][4-[2-(1-piperidinyl)ethoxy]phenyl]methanone (Evista), is a benzothiophene derivativethat differs slightly from the triphenylethyleneSERMs. A key structural difference is the carbonyl “hinge”that connects the modified phenolic side chain to the benzothiophenering system. This hinge is the key structural elementthat leads to the differing actions at the ERs.Raloxifene, unlike tamoxifen and toremifene, has antagonistproperties on the endometrium and breast tissue and agonistproperties on bone and the cardiovascular system. The lackof agonist action on endometrial tissue has been suggestedas a reason for the lack of endometrial cancer associatedwith raloxifene use. Raloxifene is approved for the preventionand treatment of osteoporosis in postmenopausalwomen. It has also been investigated for preventing breastcancer in comparison with tamoxifen. Recent studies indicatesthat it has similar effectiveness to tamoxifen, but has apreferable side effect profile.
Biological Activity
Selective estrogen receptor modulator (SERM) that binds to ER α and ER β , and tissue-dependently activates or blocks estrogen-induced transcription. Acts as an antiestrogen in breast and uterine tissue, but displays estrogen agonist activity in bone. In D12 rat hypothalamic cells, inhibits progesterone receptor induction by estrogen with an IC 50 of 1 nM.
Clinical Use
Raloxifene, the first SERM approved for the prevention of osteoporosis in postmenopausal women, acts as an estrogen agonist on receptors in osteoblasts and osteoclasts but as an antagonist at breast and uterine estrogen receptors.
Raloxifene Preparation Products And Raw materials
Supplier | Tel | Country | ProdList | Advantage | |
---|---|---|---|---|---|
Wuhan senwayer century chemical Co.,Ltd | +undefined-27-86652399 +undefined13627115097 | market02@senwayer.com | China | 898 | 58 |
Anhui Ruihan Technology Co., Ltd | +8617756083858 | daisy@anhuiruihan.com | China | 994 | 58 |
Henan Tianfu Chemical Co.,Ltd. | +86-0371-55170693 +86-19937530512 | info@tianfuchem.com | China | 21668 | 55 |
career henan chemical co | +86-0371-86658258 +8613203830695 | sales@coreychem.com | China | 29892 | 58 |
Hubei Jusheng Technology Co.,Ltd. | 18871490254 | linda@hubeijusheng.com | CHINA | 28180 | 58 |
Xiamen AmoyChem Co., Ltd | +86-592-6051114 +8618959220845 | sales@amoychem.com | China | 6387 | 58 |
Chongqing Chemdad Co., Ltd | +86-023-6139-8061 +86-86-13650506873 | sales@chemdad.com | China | 39916 | 58 |
CONIER CHEM AND PHARMA LIMITED | +8618523575427 | sales@conier.com | China | 49391 | 58 |
Chengdu Aslee Biopharmaceuticals, Inc. | 28-85305008 | CHINA | 964 | 58 | |
Hubei Ipure Biology Co., Ltd | +8613367258412 | ada@ipurechemical.com | China | 10326 | 58 |
View Lastest Price from Raloxifene manufacturers
Image | Update time | Product | Price | Min. Order | Purity | Supply Ability | Manufacturer | |
---|---|---|---|---|---|---|---|---|
![]() |
2023-11-27 | Raloxifene
84449-90-1
|
US $1330.00 / kg | 0.1kg | 99% min | 20 tons | Wuhan Senwayer Century Chemical Co.,Ltd | |
![]() |
2023-09-06 | Raloxifene
84449-90-1
|
US $30.00 / kg | 1kg | 99% | 1000t/year | Anhui Ruihan Technology Co., Ltd | |
![]() |
2023-03-17 | Raloxifene
84449-90-1
|
US $1.00 / g | 10g | 99.8% | 3000000 | Hebei Endun Biological Technology Co. LTD |
-
- Raloxifene
84449-90-1
- US $1330.00 / kg
- 99% min
- Wuhan Senwayer Century Chemical Co.,Ltd
-
- Raloxifene
84449-90-1
- US $30.00 / kg
- 99%
- Anhui Ruihan Technology Co., Ltd
-
- Raloxifene
84449-90-1
- US $1.00 / g
- 99.8%
- Hebei Endun Biological Technology Co. LTD